News
Stay up to date on the latest crypto trends with our expert, in-depth coverage.
1Bitget UEX Daily | Israel-Lebanon Talks Boost Ceasefire Expectations; S&P 500 and Nasdaq Seven Consecutive Gains; Intel-Google Collaboration Hits New Stock High (April 10, 2026)2Bitcoin moved back above the $69.4K Traders' Lower Realized Price after ceasefire headlines, signaling a potential trend shift if bulls defend the level.3Asia-Pacific Markets Surge Following Iran Ceasefire – Yet the Momentum Is Fueled by Behavioral Biases Rather Than Core Fundamentals
SEC is seeking to regain crypto ground following 'missed opportunity,' Chairman Atkins says
The Block·2026/02/27 22:42
Nvidia Surpasses Apple to Become TSMC's Largest Customer as Trading Volume Drops to 31st Place
101 finance·2026/02/27 22:39
Newmont vs. Barrick Clash Drives $1.92 Billion 68th-Ranked Trading Surge Amid Gold Venture Dispute
101 finance·2026/02/27 22:39
AppLovin Stock Falls 2.28% as SEC Probes, $2.11 Billion Trading Volume Places It 58th in Market Turnover
101 finance·2026/02/27 22:36
Salesforce's 2.35% Drop and 36th-Ranked $3.13B Volume Reflect AI Monetization Doubts Amid SaaS Sector Sell-Off
101 finance·2026/02/27 22:36
Flash
22:12
Recorded an eight-day consecutive riseGlonghui April 11｜The three major US stock indexes closed mixed, with the Nasdaq up 0.35% and recording an eight-day winning streak, the S&P 500 down 0.11%, and the Dow Jones down 0.56%. On the weekly level, the Nasdaq rose 4.68% this week, the S&P 500 climbed 3.56%—marking its largest single-week gain since November last year—and the Dow Jones gained 3.14%. Most technology stocks rose, with Broadcom up more than 4%, AMD up more than 3%, NVIDIA and Amazon both up more than 2%. Intel rose 1.07% today and surged 24% this week, achieving its largest single-week gain since January 2000.
22:11
Replimune's skin cancer drug is rejected again by the US FDA, causing the company's stock price to plummetReplimune expressed opposition to the FDA’s decision, with the company’s Chief Executive Officer (CEO) stating that, given the robust efficacy and favorable safety data supporting the drug, the FDA failed to exercise regulatory flexibility to meet patient needs.
21:53
Propanc Biopharma has filed documents with the U.S. Securities and Exchange Commission regarding a reselling plan of common shares initiated by selling shareholders.According to the filing information, the maximum number of common shares proposed for resale under this plan is up to 15 million shares. This submission signals that the selling shareholders may conduct large-scale share sales in the public market. Relevant details have been specified in the SEC filing, and the market will closely monitor the potential impact of this move on the company’s equity structure and the secondary market share price.
News